Steroid tapering showdown: which method wins for RA patients?
NCT ID NCT07227428
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two strategies for slowly reducing prednisolone (a steroid) in people with stable rheumatoid arthritis. One method splits a 5 mg tablet into halves, the other reduces by 1 mg at a time. Over six months, 206 participants will be followed to see which approach keeps disease activity low while successfully stopping steroids. The goal is to create a safer, evidence-based tapering plan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Prednisolone
- What this could lead to
- If successful, this could provide a clear, safer method for reducing long-term steroid use in rheumatoid arthritis, lowering side effects like bone loss and infection risk.
- What could go wrong
- This is a phase 4 study with 206 participants, so results may not apply to all patients. Tapering steroids can sometimes trigger disease flares or adrenal insufficiency.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Learning to Self-Care: a new approach to ease RA stiffness?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?
- Can less be more? trial tests cutting RA medication doses
- Can a new pill tame rheumatoid arthritis when standard drugs fail?
- Can two common drugs tame rheumatoid arthritis?